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Early detection and prevention of diabetic nephropathy: A
challenge calling for mandatory action for Mexico and the
developing world. During the last decades, developing coun-
tries have experienced an epidemiologic transition character-
ized by a reduction of infectious diseases and an increase of
chronic degenerative diseases. This situation is generating tor-
menting public health, financial, and social consequences. Of
particular relevance is type 2 diabetes mellitus and its chronic
complications, particularly cardiovascular disease and diabetic
nephropathy, because mortality of the patient with diabetes is,
in most instances, related to these complications.
There is a clear need to implement diagnostic and treatment
strategies to reduce risk factors for development of diabetes
(primary prevention), to detect risk factors of chronic compli-
cations in early stages of diabetes (secondary prevention), and
to prevent further progression of those that already have re-
nal injury (tertiary prevention). Microalbuminuria is an early
marker of renal injury in diabetes, and its early detection can
help the timely use of renal preventive measures, which would
avoid the extremely high costs of renal replacement treatment
for end-stage renal disease as well as that of other cardiovascu-
lar complications.
Preventive strategies are of very little or no impact, if the pri-
mary physician has limited knowledge about the natural history
of diabetic nephropathy, the beneficial effect of early preventive
maneuvers for delaying its progression, and the social and eco-
nomic impact of end-stage renal disease. It is therefore imper-
ative to assure in our health systems that general practitioners
have the ability and commitment to detect early diabetes com-
plications, in order to promote actions that support regression
or retard highly morbid cardiovascular and renal conditions.
DEMOGRAPHIC AND EPIDEMIOLOGIC
TRANSITION
During the second half of the last century, the world
experienced highly significant demographic and epidemi-
ologic changes, some of which have positively influenced
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life expectancy and the public health scenario in most na-
tions. Some of the most important changes worth men-
tioning are: major improvements of general sanitation
procedures, the development of specific public health in-
terventions, and the advent of specific medical therapies
including vaccination and antibiotics. This improvement
in life expectancy has conditioned major global demo-
graphic changes, with those observed in developing na-
tions being particularly significant.
While incidence of infectious diseases has been consis-
tently declining, chronic diseases have become the main
cause of morbidity and mortality in most of the emerg-
ing world, a trend initiated decades before in developed
countries. Figure 1 shows mortality causes in Mexico in
1940 as compared with those in the year 2000; these data
clearly support the previous statement. Parallel to the
increase in life expectancy, there has been a worldwide
declination of fertility and birth rates with consequent in-
crease in the mean age of populations; this being more
pronounced in the developing world [1, 2]. The increased
length of human life is a consequence of a combination of
several factors including: reduction of malnourishment,
advances in medical practice and technology, in particular
those related to communicable and perinatal diseases, ur-
banization, education initiatives, development of public
health programs and, as previously mentioned, the imple-
mentation of adequate sanitation practices [3]. In Mexico,
one of the major achievements during the last century was
indeed reduction in mortality. Life expectancy of Mexi-
cans has risen more than double in less than 7 decades,
increasing from a mean of 36 years in 1930 to 75 years
in 2000 [4]. The National Population Council of Mexico
has estimated the change in the shape of the population
pyramid from its actual status (Fig. 2A) to a significantly
different change in 2005 (Fig. 2B), in which the actual
high number of young people under 20 years of age will
be substituted by a much older population [5].
These demographic changes are linked to an epi-
demiologic transition characterized by a reduction of
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Fig. 1. Mortality causes in Mexico in 1940
compared with those from the year 2000. Pre-
dominance of infectious causes has shifted to
chronic degenerative diseases.
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Fig. 2. (A) Population pyramid of Mexico for the year 2000. Data obtained from the 2000 National Census. (B) Estimation of the shape of the
population pyramid of Mexico for the year 2005. Data calculated by the National Population Council of Mexico.
communicable infectious diseases and an increase in the
incidence and prevalence of chronic degenerative non-
communicable diseases. This complex and continuous
evolving process has modified the scenario and required
an urgent modification of health policies. Of particular
relevance is the change of the burden of disease usually
present in younger groups to the adult population, partic-
ularly the elderly. Additionally, the disease processes in
infectious illnesses, which were usually short and evolved
either to cure or death, have changed to what is observed
in chronic diseases, which is usually longstanding and may
require continuous medical care and treatment for years
or even decades [1, 2, 6, 7].
In addition, other demographic phenomena have con-
tributed to a shift to the current complex scenario, in
which chronic maladies predominate as responsible for
a high percentage of the health budget of the developing
world. Industrialization and development have favored
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the migration of extensive rural populations to urban and
suburban areas. Accelerated urbanization has been char-
acterized in the emerging world by the appearance of ex-
tensive areas of irregular settlements located in the out-
skirts of major cities, which lack adequate urban sanitary
and general services and medical care facilities. Two of the
most relevant features of the marginality in which these
suburban communities develop are extensive poverty and
lack of access to medical care.
Massive industrialization and development have fa-
vored almost universal changes in lifestyle and dietary
habits, with a predominance of some unhealthy ones
such as sedentary life, high fat and high carbohydrate
diets, high sodium consumption, and smoking, among
others. Highly developed and industrialized nations have
been able to progressively establish some educational
and regulatory strategies to counterbalance the commer-
cial forces that promote these unhealthy habits, therefore
conditioning a loss of consumers and advocates. In con-
trast, poorer nations have become the target of advertis-
ing and promotion of corporations that visualize these
regions of the world as unregulated, uneducated, and
highly attractive markets for consumption of unhealthy
products such as the ones previously mentioned. For ex-
ample, during the last couple of decades, tobacco smoking
has become significantly higher in the underdeveloped
world, a situation that has been accompanied by aggres-
sive and poorly regulated advertising. This factor has
imposed an additional burden on the health system of so-
cieties, which already have extremely high growth rates of
chronic pathologic conditions such as cardiovascular dis-
eases, diabetes mellitus, obesity, chronic renal diseases, or
cancer; these conditions are negatively impacted by such
dietary and lifestyle habits [6–12].
The continuous increase in metabolic, cardiovascular,
and neoplastic chronic diseases is already generating dev-
astating public health and financial and social conse-
quences in most emerging nations that cannot cope with
the cost burden of technology-driven medical interven-
tions and drugs needed to treat these diseases. To make
matters worse, the near future foresees a continued in-
crease in the incidence of these diseases as a consequence
of increased life expectancy, and this is particularly true
for Mexico. It is therefore clear that preventive strategies
may play a central role in modifying the expected pub-
lic health scenario, given the actual trends of increase of
chronic diseases.
Growth of type 2 diabetes mellitus
Of particular relevance among chronic degenerative
diseases and major contributors to excess morbidity and
mortality present in Mexico are non-insulin–dependent
or type 2 diabetes mellitus and its chronic complica-
tions, particularly cardiovascular disease and diabetic
nephropathy.
Mortality of the patient with diabetes is, in most in-
stances, related to cardiovascular and renal complications
that require costly medical procedures and which may im-
pose an even larger financial burden to the system [13].
Indeed, type 2 diabetes mellitus may well be the largest
health problem we face in Mexico during the 21st cen-
tury. This is similar to what is happening in most other
latitudes of the planet, yet to a larger extent, given the
very high prevalence of the disease and its complications
[12]. Growth of type 2 diabetes mellitus prevalence is ex-
pected to happen worldwide; nevertheless, developed na-
tions such as those in the European Union or the United
States are expecting an increase between 40% and 70%
in the next 30 years, whereas growth in developing areas
of the world, including Mexico, will be around 250% in
the same period of time.
Worldwide, Mexico has one of the most elevated type
2 diabetes mellitus prevalence. This survey shows a gen-
eral prevalence of around 25% in the general population
between 25 and 40 years of age [14]. The Mexican Sur-
vey of Chronic Diseases, performed in 1993, showed a
general prevalence in the total Mexican population of
8.2% of type 2 diabetes mellitus and, in addition, almost
one third of those diagnosed with the disease did not
know they had it [15]. These high numbers are related
to genetic predisposition [16, 17], in conjunction with in-
creased life expectancy and the changes in human behav-
ior and lifestyle that occurred in our country over the last
century, which is associated with the demographic and
epidemiologic transition discussed above [4, 18]. Type 2
diabetes mellitus has, in the last century, become a major
cause of mortality in the Mexican population as well as
the first cause of premature disability. Figure 3 shows the
mortality related to diabetes mellitus in Mexico during
the 8 eight decades. It is clear that the trend is moving to
a continuous increase in mortality due to this disease; in
1992, the mortality rate was of 2.5 × 100,000 inhabitants,
and for the year 1997 it was 15 times higher [18]. The Min-
ister of Health of Mexico recently stated that this trend
is expected to continue; deaths from diabetes frequently
linked to obesity are increasing by 3% each year, and di-
abetes mellitus itself has become Mexico’s leading cause
of death, representing 12% of total deaths in the country
[19].
Prevention of diabetes complications
The International Society of Nephrology held, in
March 2004 at the Bellagio Study and Conference Center
of the Rockefeller Foundation, a highly relevant work-
shop devoted to the discussion of strategies and ac-
tions directed toward the prevention of renal diseases
in the emerging world. Discussion was focused mainly on
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Fig. 3. Mortality related to diabetes mellitus
in Mexico during the last decades. Adapted
from [18].
pathogenetic issues associated with vascular injury, dia-
betes mellitus, and hypertension, epidemiologic analysis
of different worldwide scenarios, and discussion of the
burden of these diseases in the emerging world. In addi-
tion, early detection and preventive strategies that have
been implemented, and other potentially useful ones,
were discussed. The conference concluded that the actual
trend of permanent increase in the incidence of diabetes
mellitus and associated renal disease requiring renal re-
placement therapy is imposing a financial burden that
cannot be met by most nations of the world. There is an
urgent need for specific strategies and programs for early
detection and prevention of vascular and renal complica-
tions of diabetes mellitus to avert the global threat of an
uncontrolled pandemic.
End-stage renal disease has indeed become a major
health threat for the whole world, yet the steeper increase
in its incidence and prevalence is happening in the devel-
oping world [2–5]. Over 1 million individuals who develop
end-stage renal disease every year require expensive re-
nal replacement therapy (dialysis or kidney transplanta-
tion). Non-insulin–dependent diabetes mellitus is by far
the major contributor to this increase in end-stage renal
disease.
Worldwide, the increased prevalence of diabetes mel-
litus has expanded the premature mortality associated
with disease due to a higher frequency of its complica-
tions [20, 21]. There is a clear need to implement diagnos-
tic and treatment strategies to reduce those risk factors
for the development of diabetes (primary prevention), to
detect in early stages in patients that already have dia-
betes and are at risk of developing chronic complications
(secondary prevention), and to prevent further progres-
sion of those that already have renal injury (tertiary pre-
vention) [22]. We are also required to strongly promote
an increase in the knowledge of risk factors as well as
preventive measures in the general public, primary care
physicians, government officials, and policy makers.
The presence of urinary albumin excretion in patients
with diabetes has been clearly identified as a risk indi-
cator for nephropathy, cardiovascular injury, and death
[22–24]. Microalbuminuria is one of the earliest mark-
ers of microvascular disease in the patient with diabetes,
and it is widely accepted that it precludes development
of overt albuminuria (>300 mg/day) and progressive re-
nal functional deterioration. Microalbuminuria may also
be associated with insulin resistance syndrome, and it is
sometimes associated with conditions such as obesity and
hypertension [25].
Medical procedures developed for preventing diabetic
nephropathy must be viewed as limited in their effec-
tiveness, because the exact pathogenic factors responsi-
ble for this condition are unknown. Some strategies that
may slow the progression of renal disease include the
maintenance of good glycemic control [26–28] and blood
pressure control, the limiting of protein intake [29–31],
changes in lifestyle including smoking cessation, prompt
treatment of urinary tract infections, and the avoidance
of potentially nephrotoxic drugs and radiographic dyes
[32].
Since the last decade, it has been well established that
intensive control of blood glucose can prevent retinal,
renal, and neuropathic complications of type 1 and 2 dia-
betes. The Diabetes Control and Complications Trial [28]
and the United Kingdom Prospective Diabetes Study [33]
were the first of several studies that established the value
of intensive control of blood glucose. Establishment of
intensive glucose control has demonstrated a reduction
in albuminuria (surrogate end point) and a prevention
or retardation in the development of diabetic nephropa-
thy leading to end-stage renal disease (actual end point)
[34, 35].
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Diabetic renal disease is accompanied by the devel-
opment of hypertension in almost all patients, and it is
well known that antihypertensive treatment delays pro-
gressive renal injury [36]. Several studies have demon-
strated that the blockade of the renin-angiotensin system
(RAAS) with angiotensin-converting enzyme inhibitors
or angiotensin II receptor blockers is of additional bene-
fit. RAAS-blocking agents administered either in early or
later stages of the disease may induce a beneficial effect in
terms of reduction of microalbuminuria and subsequent
reduction of progressive renal injury [36–41]. The patho-
physiologic participation of the RAAS in renal injury of
diabetic renal disease, and the subsequent implementa-
tion of pharmacologic interventions to block this system,
have modified our ability to treat the patient with di-
abetes with nephropathy. It is clear that the beneficial
renoprotective effect of the RAAS blockade is, in part,
independent of the antihypertensive mechanism and may
induce reduction or regression of microalbuminuria in
early states of renal injury, even in the absence of hyper-
tension.
The fact that microalbuminuria is an early marker of
renal injury has allowed its application as a monitoring
instrument of early stages of the disease [25, 31, 35, 37],
and the timely identification of diabetics that can ben-
efit from the renal protective effects of blockade of the
RAAS system and other preventive measures. Given the
extremely high costs of renal replacement treatment for
end-stage renal disease as well as that of other cardio-
vascular complications, it is clear that this procedure may
be highly cost-effective and an invaluable aid to mitigate
the very large financial burden of treating end-stage re-
nal disease. It may also favor better patient outcomes
in countries of the developing world [29–31, 34]. Actu-
ally, we believe that this approach may be the way of the
future, in terms of control of an epidemic growth of di-
abetes mellitus, diabetic nephropathy, and other chronic
vascular diseases.
It is clear that preventive actions must be implemented
as early as possible in the evolution of diabetes; however,
multiple situations have precluded timely actions. Some
of the most relevant are the absence of overt symptoms
in most patients, lack of health-related education of the
general population, lack of knowledge of primary care
physicians about the importance of preventive measures,
lack of commitment by the medical community, delayed
referral to nephrologists and, of course, scarce resources
for preventive medicine from national health systems
[42]. Development and execution of successful preven-
tive programs require joint efforts that include the par-
ticipation of patients and their relatives, physicians and
other health workers, national government agencies, the
pharmaceutical industry, and international agencies. Of
utmost importance is to raise awareness and to educate
the general public, patients, policymakers, and primary
physicians in charge of patients on the importance of gen-
erating changes in lifestyle conditions that may reduce the
risk of development of chronic conditions, and on those
simple maneuvers directed to early detection of risk fac-
tors. In parallel with educational efforts, we need effective
programs geared toward early detection of risk factors.
Blood glucose and systemic blood pressure monitoring
play a key role in this issue. In addition, periodic determi-
nation of microalbuminuria is of particular importance,
given its known value as an indicator of progressive renal
and vascular disease. Once early stages of renal disease
are diagnosed, simple procedures need to be put in place,
again emphasizing lifestyle changes (reduction in sodium
intake and other dietary indications) and early pharma-
cologic interventions that should include RAAS block-
ade and possibly other drugs such as low-dose aspirin or
statins, if hyperlipidemia is present [43].
Validation of an educational program for primary
physicians
In spite of the availability of clear opportunities for
intervention at almost any stage of diabetic nephropa-
thy, preventive strategies are of very little or no impact,
if the primary physician who is the first medical contact
of the general community has limited knowledge about
the natural history of diabetic nephropathy, the benefi-
cial effect of early preventive maneuvers for delaying its
progression, and the social or economic impact of end-
stage renal disease. It is therefore imperative to assure
in our health systems that general practitioners and fam-
ily physicians have the ability and commitment to detect
early manifestations of diabetes mellitus complications,
and to promote the prescription of lifestyle changes and
medication that favor regression or retard highly morbid
cardiovascular and renal conditions. In addition, contin-
ued professional development for health care is an impor-
tant tool for health improvement of communities, and it
is considered as a means to maintain high standards of
care as well as of improvement on recruiting, motivating,
and retaining high quality staff [44].
Although the process needed to create infrastructure
and local educational programs has to be planned from
the inside of each country considering special needs
and characteristics of the society where it will be im-
plemented, global assistance, when possible, may be
highly supportive. This may assure greater success and a
higher retention of health workers and physicians in the
programs.
There is scarce information related to the implemen-
tation and results of continuous medical education pro-
grams directed to first-contact physicians and aimed to
modify knowledge and prescription practices of primary
and secondary prevention of diabetic kidney disease. In
Mexico, we are conducting a research and educational
S-74 Correa-Rotter and Gonza´lez-Michaca: Diabetic nephropathy prevention in Mexico
project directed to first-contact physicians and aimed at
primary and secondary prevention of diabetic kidney dis-
ease. We believe that programs of this nature may lead to
a reduction of the growth in the number of diabetic end-
stage renal diseases requiring renal replacement therapy,
and therefore may lead to a decrease in associated mor-
tality. The project includes the development, validation,
and establishment of an educational program in the pub-
lic health sector at the national level oriented to train gen-
eral practitioners and family physicians in the knowledge
of basic pathophysiology, natural history and, specifically,
on prevention and treatment strategies for early compli-
cations of diabetes mellitus, with emphasis on diabetic
nephropathy. In addition, we have specifically designed
instruments for this purpose, in order to evaluate partic-
ipants’ knowledge at the moment of the program’s ini-
tiation and its impact on the acquisition of knowledge
and the short and midterm modification of diagnostic and
therapeutic attitudes directed to reduction of progression
of renal injury. Finally, another objective is to generate in-
creased awareness, motivation, and self assurance on the
importance of primary care physicians’ intervention for
national public health purposes.
This project has been developed by a group of nephrol-
ogists, in conjunction with other professionals (epi-
demiologist, sociologist, and teaching professionals), and
includes oral presentations, written documents, posters
with algorithms, as well as directed case discussions. Once
developed, it will be applied and validated by means of
an experimental study, in which selected health centers
will be randomly chosen to participate as experimental
or control centers. Physicians from control health centers
will receive standard educational and information oppor-
tunities, yet no specific, directed intervention will be pro-
vided to physicians of experimental centers. Both will be
evaluated and monitored in the same form, so that the re-
sults can be compared. The capacity to modify diagnos-
tics and therapeutic attitudes in the educative program
will be measured by evaluation of participant physicians
before and after receiving the qualification on diabetic
nephropathy, and comparing these results with practices
of physicians from control centers (patient questionnaires
exploring medical indications and recommendations at 6
months after implementation of the program, and pa-
tient chart comparisons on indications and prescriptions
after the educational maneuver at 6 months after the pro-
gram is concluded). This is a nationwide program to be
implemented initially by 30 collaborating nephrologists,
educators, and health promoters (educators and coinves-
tigators), who will be carefully trained in a standardized,
educational program that is to be provided to 600 general
practitioners. Based on the obtained results, a proposal
will be developed to implement a permanent national
program of education in diabetic nephropathy and other
microvascular complications of this disease, and to gen-
erate the Mexican guidelines for primary and secondary
prevention of diabetic kidney disease. Funding and sup-
port for this initiative have been obtained from Mexican
government agencies (National Council for Science and
Technology) and from the pharmaceutical industry. Suc-
cess in obtaining the goals of the project is of utmost im-
portance to provide additional evidence of the benefit of
investing on education to promote prevention of chronic
diseases.
CONCLUSION
Action for control of chronic complications of diabetes
mellitus requires immediate attention that cannot be de-
layed because this could prove to be extremely costly
for emerging nations. An adequate policy implies, among
other strategies, the initiation of extensive educational
strategies, extrapolating knowledge previously obtained
elsewhere with simultaneous development of local ini-
tiatives that may allow us to better understand and face
local conditions.
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